Jane Street’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-37,400
Closed -$4.93M 11371
2025
Q1
$4.93M Buy
37,400
+26,000
+228% +$3.24M ﹤0.01% 2957
2024
Q4
$952K Sell
11,400
-8,100
-42% -$666K ﹤0.01% 5485
2024
Q3
$1.43M Buy
19,500
+100
+0.5% +$7.52K ﹤0.01% 5163
2024
Q2
$1.33M Sell
19,400
-33,400
-63% -$2.32M ﹤0.01% 5222
2024
Q1
$3.65M Buy
52,800
+2,700
+5% +$186K ﹤0.01% 3093
2023
Q4
$3.59M Buy
50,100
+26,200
+110% +$1.51M ﹤0.01% 3345
2023
Q3
$1.24M Buy
23,900
+11,000
+85% +$641K ﹤0.01% 4844
2023
Q2
$817K Sell
12,900
-167,600
-93% -$10.4M ﹤0.01% 5548
2023
Q1
$9.77M Buy
180,500
+143,300
+385% +$6.93M ﹤0.01% 1666
2022
Q4
$1.97M Sell
37,200
-83,700
-69% -$4.19M ﹤0.01% 3896
2022
Q3
$5.63M Sell
120,900
-88,300
-42% -$4.61M ﹤0.01% 2418
2022
Q2
$11.9M Buy
209,200
+135,200
+183% +$7.67M 0.01% 1550
2022
Q1
$4.53M Sell
74,000
-48,800
-40% -$2.53M ﹤0.01% 3193
2021
Q4
$6.43M Buy
122,800
+70,400
+134% +$2.96M ﹤0.01% 2474
2021
Q3
$1.95M Buy
52,400
+17,900
+52% +$622K ﹤0.01% 4525
2021
Q2
$1.41M Buy
34,500
+23,600
+217% +$872K ﹤0.01% 5065
2021
Q1
$370K Sell
10,900
-12,900
-54% -$448K ﹤0.01% 7357
2020
Q4
$757K Sell
23,800
-57,300
-71% -$1.51M ﹤0.01% 5113
2020
Q3
$2.08M Sell
81,100
-147,500
-65% -$3.37M ﹤0.01% 2976
2020
Q2
$5.87M Buy
228,600
+215,300
+1,619% +$4.36M ﹤0.01% 1670
2020
Q1
$204K Sell
13,300
-149,900
-92% -$3.26M ﹤0.01% 4633
2019
Q4
$5.6M Buy
+163,200
New +$1.96M 0.01% 988
2017
Q2
Sell
-36,900
Closed -$600K 4983
2017
Q1
$600K Buy
+36,900
New +$534K ﹤0.01% 2665

Other funds holding ITCI

Jane Street's ITCI Position: Q2 2025 in Review

Jane Street sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 132,909 shares — an estimated $17.5M sold.

Jane Street first reported a position in ITCI in Q2 2014 and held it in 28 quarters. The position peaked at $33M in Q2 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Jane Street reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Jane Street sold 132,909 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $17.5M.
  • Jane Street first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 28 quarters.
  • Jane Street's Intra-Cellular Therapies Inc. position peaked at $33M in Q2 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Jane Street's 13F filing for Q2 2025, filed 14 Aug 2025.